Rheumatoid Arthritis

Joint autoimmunity initiated by NET-osis in a pro-inflammatory oxidized lipid environment. The citrullinated proteins driving anti-CCP antibodies are generated by the same oxidative machinery this protocol addresses.

The Initiating Event — NET-osis

Neutrophil extracellular traps (NETs): activated neutrophils extrude webs of nuclear chromatin (DNA + histones + antimicrobial proteins) into the extracellular space.

PAD4 (Peptidylarginine Deiminase 4): citrullinates arginine residues in histone proteins within NETs. Citrullination converts the positively charged arginine to neutral citrulline, fundamentally changing the protein's immunogenicity.

Citrullinated proteins from NETs → anti-CCP (anti-cyclic citrullinated peptide) antibody production by B cells → the defining autoantibody of RA.

How oxidized lipids initiate this:

• OXLAMs directly stimulate NET formation through TLR4 and CD36 on neutrophils
• The more dietary OXLAMs, the more NET-osis, the more citrullinated antigen, the more anti-CCP antibody production
• The fat maintenance protocol removes this stimulus upstream

Synovial Ectopic Lymphoid Tissue

The synovium becomes a tertiary lymphoid organ — ectopic germinal centers where B cell activation and antibody production occurs within the joint itself. This is driven by:

• Impaired synovial macrophage efferocytosis failing to clear cellular debris that maintains local antigen presentation
• Continued antigen load from NET-osis within the joint space

Local aromatase expression in the synovium converts androgens to estrogens locally → pro-inflammatory estrogenic microenvironment → amplified B cell response → higher antibody titers.

Baicalin (Scutellaria) — RA Specific

Baicalin specifically:

• Inhibits PAD4 directly — prevents the citrullination that creates the RA autoantigen
• This is mechanistically elegant: addressing the antigen production step rather than downstream inflammation
• Also inhibits STAT6 (IgE switching) and Th17 differentiation

Protocol Additions for RA

Beyond the standard protocol:

• Low-dose aspirin (81mg): Aspirin-triggered lipoxins (15-epi-LXA4) specifically activate efferocytosis of apoptotic neutrophils (the NET-otic cells). NET clearance reduces the antigen burden sustaining the RA synovial response.
• Vitamin D3 at higher dose (5000–10000 IU with K2): Specifically suppresses Th17 differentiation driving synovial inflammation; directly reduces BAFF (B cell survival factor)
• Baicalin/skullcap: PAD4 inhibition — the RA-specific mechanism

Connections

• [[Efferocytosis Failure]] — synovial macrophage failure sustaining antigen presentation
• [[Estrobolome]] — local synovial aromatase connection
• [[Oxidized Lipid Cascade]] — NET-osis initiation
• [[Phase 2 - Mast Cell Stabilization]] — baicalin inclusion
• [[EDS-MCAS-Eczema Cluster]] — shared upstream drivers